ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket – Seeking Alpha
Smarter Analyst |
ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket
Seeking Alpha ZIOPHARM Oncology (NASDAQ:ZIOP) perks up 5% premarket on light volume on the heels of its announcement that it has received FDA guidance from an End-of-Phase 2 meeting regarding lead gene therapy candidate Ad-RTS-hIL-12, in combination with … ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent … ZIOPHARM Oncology (ZIOP) Stock: Gains On Positive FDA Guidance |
